Orthopedics – Q1 2022 Acquisition Activity and Outlook
The 1st quarter of 2022 delivered nine reported orthopedic practice acquisitions, continuing the trend of increasing deal volume.
Ophthalmology – Q1 2022 Acquisition Activity and Outlook
The first quarter of 2022 delivered eleven reported ophthalmology practice acquisitions, marking a sharp decline from the flurry of closings at the end of last year This was expected as business development teams had exhausted all resources toward closing deals last quarter We will highlight a few notable deals.
Home Health & Hospice – Q1 2022 Acquisition Activity and Outlook
The first quarter of 2022 delivered twenty-eight reported home health and hospice acquisitions, coming down from peaks levels to end the past year However, Q1 has historically brought lower M&A levels, and we expect deal volume to rebound throughout the year.
Gastroenterology – Q1 2022 Acquisition Activity and Outlook
The first quarter of 2022 delivered ten reported gastroenterology practice acquisitions, continuing the high level of M&A activity we saw last year Several deals were announced in the first few weeks of the year, likely spilling over from efforts to close in 2021.
ENT & Allergy – Q1 2022 Acquisition Activity and Outlook
The first quarter of 2022 delivered two reported ENT practice acquisitions, coming down from a flurry of deal activity to end last year.
Dermatology – Q1 2022 Acquisition Activity and Outlook
The 4th quarter of 2021 delivered two reported cardiology platform acquisitions, signaling an imminent wave of increasing private equity investments into the specialty.
Behavioral Health – Q1 2022 Acquisition Activity and Outlook
The first quarter of 2022 delivered thirty-five reported behavioral health acquisitions, returning to average deal volume after a spike in activity to end 2021. Mental health and addiction treatment continue to be at the forefront of consolidation. We will highlight a few notable deals from the period.
Cardiology – Q1 2022 Acquisition Activity and Outlook
The 1st quarter of 2022 delivered two reported cardiology partnerships for this specialty in the Early Pioneering lifecycle stage PE interest remains consistent and seems to be building
FOCUS Investment Banking Represents Vista Eye Specialists in its Sale to Atlantic Vision Partners, LLC
Washington, DC, (February 14, 2022) – FOCUS Investment Banking (“FOCUS”), a national middle market investment banking firm providing merger, acquisition, divestiture, and corporate finance services, announced today that Vista Eye Specialists, an ophthalmologic and optomet- ric practice, has been acquired by Atlantic Vision Partners (“AVP”), a portfolio company of Sheridan Capital Partners. FOCUS managing directors, Eric Yetter and Andy Snyder, advised Vista Eye Specialists in this partnership.They are among the most active advisors to ophthal- mologists in transactions with private equity-backed organizations.
FOCUS Investment Banking continues to rank #1 in Axial’s Top 20 Lower Middle Market Investment Banks for 4Q 2021
Washington, DC, (January 21, 2022) – FOCUS Investment Banking (“FOCUS”), a leading national middle market investment banking firm providing merger, acquisition, divestiture, and corporate finance services, is delighted to be acknowledged as #1 on Axial’s Top Lower Middle Market M&A Advisors list for Q4 2021. This marks the second consecutive quarter the firm has received this recognition.
